1. Home
  2. CTNM vs BYND Comparison

CTNM vs BYND Comparison

Compare CTNM & BYND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • BYND
  • Stock Information
  • Founded
  • CTNM 2009
  • BYND 2009
  • Country
  • CTNM United States
  • BYND United States
  • Employees
  • CTNM N/A
  • BYND N/A
  • Industry
  • CTNM
  • BYND Packaged Foods
  • Sector
  • CTNM
  • BYND Consumer Staples
  • Exchange
  • CTNM Nasdaq
  • BYND Nasdaq
  • Market Cap
  • CTNM 248.7M
  • BYND 214.6M
  • IPO Year
  • CTNM 2024
  • BYND 2019
  • Fundamental
  • Price
  • CTNM $12.16
  • BYND $2.08
  • Analyst Decision
  • CTNM Strong Buy
  • BYND Sell
  • Analyst Count
  • CTNM 5
  • BYND 5
  • Target Price
  • CTNM $22.20
  • BYND $96.50
  • AVG Volume (30 Days)
  • CTNM 194.4K
  • BYND 8.5M
  • Earning Date
  • CTNM 11-05-2025
  • BYND 11-05-2025
  • Dividend Yield
  • CTNM N/A
  • BYND N/A
  • EPS Growth
  • CTNM N/A
  • BYND N/A
  • EPS
  • CTNM N/A
  • BYND N/A
  • Revenue
  • CTNM N/A
  • BYND $301,353,000.00
  • Revenue This Year
  • CTNM N/A
  • BYND N/A
  • Revenue Next Year
  • CTNM N/A
  • BYND $0.73
  • P/E Ratio
  • CTNM N/A
  • BYND N/A
  • Revenue Growth
  • CTNM N/A
  • BYND N/A
  • 52 Week Low
  • CTNM $3.35
  • BYND $1.23
  • 52 Week High
  • CTNM $20.24
  • BYND $6.81
  • Technical
  • Relative Strength Index (RSI)
  • CTNM 56.27
  • BYND 41.76
  • Support Level
  • CTNM $10.65
  • BYND $2.19
  • Resistance Level
  • CTNM $12.14
  • BYND $2.65
  • Average True Range (ATR)
  • CTNM 0.92
  • BYND 0.26
  • MACD
  • CTNM -0.21
  • BYND -0.03
  • Stochastic Oscillator
  • CTNM 34.98
  • BYND 54.99

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About BYND Beyond Meat Inc.

Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.

Share on Social Networks: